CIBC and RBC Accused of Manipulating Quantum Stock Prices in Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Source: PRnewswire
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they manipulated trades to artificially deflate the stock price of Quantum Biopharma Ltd. (NASDAQ:QNTM) during the period from January 6, 2021, to October 15, 2025.
- Fraudulent Tactics: The complaint alleges that the defendants repeatedly placed thousands of spoofed sell orders to create a false impression of declining stock prices, which deceived investors into selling their shares at artificially depressed prices, allowing the defendants to profit by purchasing shares at these lower levels.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at artificially low prices, leading to significant financial losses, which could undermine market confidence in Quantum's stock.
- Legal Implications: Investors have until February 23, 2026, to apply to be lead plaintiffs, with the law firm offering services on a contingency fee basis, demonstrating a strong commitment to protecting investor rights and restoring capital integrity in the marketplace.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like QNTM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and further depress stock prices.
- Manipulative Trading Allegations: The complaint accuses financial institutions like CIBC and RBC of placing thousands of spoofed sell orders to create a false impression of declining stock prices, leading other investors to sell at artificially low prices and incurring significant losses.
- Investor Rights Protection: Shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting their strong concerns regarding corporate governance and transparency.
- Law Firm Credentials: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, is dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
Continue Reading
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and lead to further stock price declines.
- False Trading Allegations: The lawsuit claims that financial institutions like CIBC and RBC executed thousands of spoofed sell orders to create a false impression of Quantum's stock price decline, misleading other investors into selling their shares at artificially low prices, thereby harming investor interests.
- Investor Action Deadline: Affected Quantum shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting the potential impact of this case on shareholder rights and its significance.
- Law Firm Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
Continue Reading